Advanced Renal Cell Carcinoma: Interpreting Depth of Response and Clinical Relevance

In this segment, the discussion focuses on the clinical significance of depth of response in advanced renal cell carcinoma and how it should be interpreted in practice. Dr. Brian Rini highlights that while deeper responses are generally associated with improved outcomes, there is no clearly defined threshold that reliably predicts benefit across patients. He explains that traditional response criteria, such as percentage tumor reduction, can be highly variable and influenced by factors including baseline tumor burden and measurement variability. The panel emphasizes that differences in response percentages may not always translate into meaningful clinical differences, particularly in cases with small-volume disease. Dr. Thomas Powles adds that relative changes in tumor size can sometimes be misleading when interpreted without clinical context. Overall, this segment underscores that while depth of response remains an important consideration, treatment decisions in advanced renal cell carcinoma should be guided by a broader clinical perspective rather than relying solely on numerical response thresholds.